Impact of taxane plus bevacizumab for ovarian sex cord tumor with annular tubules
Impact of taxane plus bevacizumab for ovarian sex cord tumor with annular tubules
复制标题
DOI：
10.1111/jog.13985
复制
发表时间：
2019-07-01
影响因子：
1.6
通讯作者：
Kobayashi, Hiroaki
中科院分区：
文献类型：
--
作者：
Sho, Takanari;Yanazume, Shintaro;Kobayashi, Hiroaki
环状小管性索肿瘤（SCTAT）是罕见的，20%的SCTAT病例（不包括与Peutz-Jeghers综合征相关的病例）在临床上是恶性的。关于化疗在SCTAT管理中的作用的数据有限。我们遇到一位44岁的女性，在右侧附件切除术后复发性SCTAT并发腹膜播散。由于肿瘤范围较广，手术切除不彻底。考虑到其恶性化的可能性，我们选择了博莱霉素、足叶乙甙和顺铂（BEP）联合化疗作为术后治疗。然而，患者在完整的BEP方案后显示部分缓解。患者接受了3个疗程的多西他赛和卡铂联合贝伐珠单抗化疗。联合化疗后，正电子发射断层扫描-计算机断层扫描证实完全缓解，目前正在继续贝伐珠单抗治疗，无复发，也无并发症的重大不良反应。该病例证明了紫杉烷和贝伐单抗联合治疗复发性SCTAT患者的潜力。
Sex cord tumor with annular tubules (SCTAT) is rare, and 20% of SCTAT cases, excluding those associated with Peutz-Jeghers syndrome, are clinically malignant. Limited data is available regarding the role of chemotherapy in the management of SCTAT. We encountered a 44-year-old woman with recurrent SCTAT complicated by peritoneal dissemination following a right adnexectomy. The surgical resection could not be performed completely due to the wide extension of the tumor. Considering the potential of becoming malignant, we chose a combination of bleomycin, etoposide and cisplatin (BEP) as postoperative chemotherapy treatment. However, the patient showed partial response following a complete BEP regimen. The patient received three courses of chemotherapy with docetaxel and carboplatin plus bevacizumab. After the combination chemotherapy, positron emission tomography-computed tomography scan confirmed a complete response, and is currently continuing bevacizumab treatment without relapsing and having no major adverse effects from complications. This case proved the potential of a combination of taxane and bevacizumab in patients with recurrent SCTAT.